Article
The Cost-Effectiveness of the Argus II retinal prosthesis system in Retinitis Pigmentosa patients
Search Medline for
Authors
Published: | February 13, 2014 |
---|
Outline
Text
Objective: To assess the cost-effectiveness of the Argus® II Retinal Prosthesis System (Argus II) in Retinitis Pigmentosa (RP) patients. Design: Decision analysis model based-comparison of long term costs and health outcomes of Argus II implantation versus usual care (i.e. nursing care and rehabilitation) in RP patients. Participants: A hypothetical cohort of 1000 RP patients aged 46 years followed up over a (lifetime) 25-year time horizon.
Method: A multi -state transition Markov model was developed to determine the cost-effectiveness of Argus II versus usual care in RP from the perspective of healthcare payer. Health outcomes were expressed as quality adjusted life years (QALYs) and direct healthcare costs expressed in 2012 €. Results are reported as incremental cost per ratios (ICERs) with outcomes and costs discounted at an annual rate of 3.5%.
Results: The ICER for Argus II was €14,603 /QALY. Taking into account the uncertainty in model inputs the ICER was €14,482/QALY in the probabilistic analysis. In the scenarios of an assumption of no reduction on cost across model visual acuity states or a model time horizon as short as 10 years the ICER increased to €31,890/QALY and €49,769/QALY respectively.
Conclusion: This economic evaluation shows that Argus II is a cost-effective intervention compared to usual care of the RP patients. The lifetime analysis ICER for Argus II falls below the published societal willingness to pay of EuroZone countries.